Amylyx Pharmaceuticals 株価情報 (NASDAQ: AMLX)

Amylyx Pharmaceuticals (NASDAQ:AMLX) 株価情報

Amylyx Pharma

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals Inc

Barclays analyst Tim Long maintains Zebra Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) with a Equal-Weight and lowers the price target from $326 to $263.

News

Price Target

Analyst Ratings

ZBRA

Barclays Maintains Equal-Weight on Zebra Technologies, Lowers Price Target to $263

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $161 to $171.

Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $171

Barclays analyst Saket Kalia maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Equal-Weight and lowers the price target from $40 to $33.

TENB

Barclays Maintains Equal-Weight on Tenable Holdings, Lowers Price Target to $33

Barclays analyst Jeffrey Bernstein maintains Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) with a Overweight and lowers the price target from $87 to $77.

Barclays Maintains Overweight on Sysco, Lowers Price Target to $77

Samsung Electronics Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) reported <a href="https://www.benzinga.com/topic/samsung" target="_blank" rel="noreferrer noopener">first-quarter revenue</a> growth of 10% year-on-year to 79.1 trillion Korean won ($55.5 billion) Wednesday.
Revenue growth marked an all-time quarterly high, driven by strong sales of flagship Galaxy S25 smartphones and <a target="_blank" href="https://www.samsung.com/global/ir/" rel="noreferrer noopener">high-value-added products</a>.
Operating profit was 6.7 trillion Korean won ($17.62 billion), up from 6.6 Korean won a year ago, despite headwinds for the DS Division.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44630345/samsungs-china-chip-pivot-gains-steam-with-54-export-surge-amid-us-market-struggles" rel="noreferrer noopener">Samsung&#8217;s China Chip Pivot Gains Steam With 54% Export Surge Amid US Market Struggles</a>
The DS Division (encompassing Memory and S.LSI / Foundry) posted revenue of 25.1 trillion Korean won (versus 23.1 trillion Korean won Y/Y).
The division reported 1.1 trillion Korean won in operating profit (versus 1.9 trillion Korean won Y/Y) due to the erosion of average selling price (ASP) and a decrease in HBM sales due to export controls on AI chips and deferred demand in anticipation of upcoming enhanced HBM3E products.
Samsung Display Corp Division (SDC) posted 5.9 trillion Korean won in revenue (versus 5.4 trillion Korean won Y/Y) and 0.5 trillion Korean won in operating profit (versus 0.3 trillion Korean won Y/Y).
The Mobile eXperience (MX) and Networks businesses posted 37.0 trillion Korean won in revenue (versus 33.5 Korean won Y/Y). The division reported 4.3 trillion Korean won in operating profit (versus 3.5 trillion Korean won Y/Y).
The quarterly capex was 12.13 trillion Korean won, down from 13.42 trillion Korean won a year ago.
Samsung&#8217;s flagship products, including semiconductors, smartphones, and tablets, are now exempt from reciprocal tariffs. Still, President Donald Trump has&nbsp;indicated&nbsp;that a tariff on the electronics supply chain, including chips, is in the works, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-30/samsung-s-chips-business-beats-estimates-after-stockpiling-push?sref=TBDibEcD" rel="noreferrer noopener">reported</a> Wednesday.
Seoul and Washington agreed to pursue a comprehensive package agreement by July 8, when the 90-day tariff pause will end.
Samsung has struggled for months to secure&nbsp;Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) final nod for its most advanced HBM products, making it challenging to compete with&nbsp;Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
Samsung is in talks to supply customized sixth-generation high-bandwidth memory, or HBM4, chips to major AI chipmakers, including Nvidia, Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, the Korea Economic Daily <a target="_blank" href="https://www.kedglobal.com/korean-chipmakers/newsView/ked202504300004" rel="noreferrer noopener">reported</a> Wednesday.
Outlook: In the second quarter, the Memory Business anticipates robust demand for AI servers and a ramp-up of the enhanced HBM3E 12H.
AI-related demand is expected to remain high in the second half, in conjunction with the launch of new GPUs.
In the second quarter, the System LSI Business will maintain steady revenue by gaining SoC adoption by a major customer for new flagship models and capitalizing on the growing adoption of 200-megapixel sensors.
In the second half, the System LSI Business will expand its flagship SoC supply and develop its automotive sensor portfolio.
In the second quarter, the Foundry Business will stabilize its 2nm process production and drive earnings improvement by actively addressing strong mobile and automotive demand in the United States. Looking ahead to the second half, the Foundry Business aims to start 2nm mass production, secure major 2nm orders, and strengthen its specialty process portfolio on mature nodes.
In the second quarter, the mobile display business maintained a conservative outlook on earnings while pursuing a stable supply of new products such as foldables.
In the second half, SDC aims to grow mobile display business sales through differentiated technologies and products.
In the second quarter, MX Business plans to sustain flagship-centric sales amid weak seasonality by successfully launching the Galaxy S25 Edge. It will also expand its AI smartphone lineup by introducing &#8220;Awesome Intelligence&#8221; to the Galaxy A series.
In the second half, the MX Business will strengthen its foldable lineup by offering a differentiated AI user experience. In addition, the Business will launch new ecosystem products with enhanced AI and health capabilities and explore new product segments such as XR.
In the second quarter, Visual Display and Digital Appliances intends to expand TV sales with its 2025 AI TV lineup and the integration of advanced AI functions.
In the second half, the Business will focus on capturing peak season demand through strategic collaboration with distributors based on an enhanced AI TV lineup.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44140452/gm-stellantis-supplier-samsung-sdi-weighs-new-us-battery-plant-amid-trumps-ev-policy-shift" target="_blank" rel="noreferrer noopener">GM, Stellantis Supplier Samsung SDI Weighs New US Battery Plant Amid Trump&#8217;s EV Policy Shift</a></li>
</ul>

Asia

Earnings

Guidance

Emerging Markets

Tech

Media

AVGO

GOOG

GOOGL

NVDA

SSNLF

Samsung Galaxy Sales Soar But Foundry Segment Lags As Trump Tariffs Loom

Barclays analyst George Wang maintains Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Equal-Weight and lowers the price target from $59 to $34.

SMCI

Barclays Maintains Equal-Weight on Super Micro Computer, Lowers Price Target to $34

Barclays analyst Jeffrey Bernstein maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Overweight and lowers the price target from $106 to $98.

SBUX

Barclays Maintains Overweight on Starbucks, Lowers Price Target to $98

Barclays analyst Kannan Venkateshwar maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Overweight and lowers the price target from $710 to $650.

SPOT

Barclays Maintains Overweight on Spotify Technology, Lowers Price Target to $650

Barclays analyst Terry Ma maintains SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a Equal-Weight and raises the price target from $11 to $12.

SOFI

Barclays Maintains Equal-Weight on SoFi Technologies, Raises Price Target to $12

Barclays analyst Tom O'Malley maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Equal-Weight and raises the price target from $80 to $90.

Barclays Maintains Equal-Weight on Seagate Tech Hldgs, Raises Price Target to $90

Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has outperformed the market over the past 5 years by 11.01% on an annualized basis producing an average annual return of 25.16%. Currently, Goldman Sachs Group has a market capitalization of $170.57 billion. 
Buying $100 In GS: If an investor had bought $100 of GS stock 5 years ago, it would be worth $311.05 today based on a price of $546.64 for GS at the time of writing.
<h3>Goldman Sachs Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746052210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Barclays analyst Brandt Montour maintains Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Overweight and raises the price target from $249 to $263.

Barclays Maintains Overweight on Royal Caribbean Gr, Raises Price Target to $263

Barclays analyst Tom O'Malley maintains Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) with a Equal-Weight and raises the price target from $60 to $70.

QRVO

Barclays Maintains Equal-Weight on Qorvo, Raises Price Target to $70

Barclays analyst Anthony Powell maintains Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) with a Overweight and lowers the price target from $132 to $119.

Barclays Maintains Overweight on Prologis, Lowers Price Target to $119

Barclays analyst Nicholas Campanella maintains Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Equal-Weight and lowers the price target from $48 to $45.

Barclays Maintains Equal-Weight on Portland Gen Electric, Lowers Price Target to $45

Barclays analyst David Anderson maintains NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) with a Underweight and lowers the price target from $13 to $11.

Barclays Maintains Underweight on NOV, Lowers Price Target to $11

Barclays analyst George Wang maintains Logitech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) with a Overweight and lowers the price target from $108 to $92.

LOGI

Barclays Maintains Overweight on Logitech International, Lowers Price Target to $92

Barclays analyst Jack Meehan maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and raises the price target from $240 to $250.

Laboratory Corporation Of America Holdings

Barclays Maintains Equal-Weight on Labcorp Hldgs, Raises Price Target to $250

Barclays analyst Anthony Powell maintains SL Green Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) with a Equal-Weight and lowers the price target from $76 to $60.

Barclays Maintains Equal-Weight on SL Green Realty, Lowers Price Target to $60

Barclays analyst Brendan Lynch maintains Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) with a Underweight and lowers the price target from $38 to $35.

REXR

Barclays Maintains Underweight on Rexford Industrial Realty, Lowers Price Target to $35

Press Releases

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

Comments

Amylyx Pharmaceuticals

ニュース

パートナーシップ

ベンジンガ・グローバル